Alan Amberg
Psychiatric/Mental Health · Chicago, ILNPI 1164725941
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 41.2% of the total. 2025 is the largest year on record at $64,126, 7.6 times the $8,413 reported in 2021. Among psychiatric/mental health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $379.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$49K
- AbbVie$34K
- Axsome Therapeutics, Inc.$21K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Janssen Scientific Affairs, LLC$2K
- plus $2K from 10 others
What the payments were for
- Consulting fees$29,73925%
- Speaking & faculty fees$62,00452%
- Travel & lodging$17,34015%
- Food & beverage$9,9138%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 95 | $49,033 |
| AbbVie(2 entities) | 107 | $34,410 |
| Axsome Therapeutics, Inc. | 41 | $20,615 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $6,527 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $4,919 |
| Janssen Scientific Affairs, LLC | 4 | $1,991 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $531 |
| Alkermes, Inc. | 9 | $449 |
| Lundbeck LLC | 4 | $194 |
| Johnson & Johnson | 2 | $120 |
| Braeburn Inc. | 3 | $68 |
| Sage Therapeutics, LLC | 2 | $54 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Neos Therapeutics, LP | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,047 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 48 | $691 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $244 |
| Propranolol Hcl | 16 | $240 |
| Sertraline Hcl | 25 | $224 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $128 |
| Mirtazapine | 15 | $69 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Chicago
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$151K
- Melissa VitaleChicago$151K
- Julie CarbrayChicago$36K
- Abigail HamiltonChicago$14K
- Anh NguyenChicago$9K
- Sherann IvyChicago$8K
- Annabella Vidal-RuizChicago$8K
- Dina Pierre-GrayChicago$7K
- Natalia RysmanowskaChicago$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.